Navigation Links
Chimerix to Present at 9th Annual BIO Investor Forum
Date:9/28/2010

RESEARCH TRIANGLE PARK, N.C., Sept. 28 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present a corporate overview at the upcoming BIO Investor Forum Conference on October 5th, 2010 at 2:00pm PT.  The conference is being held at the Palace Hotel in San Francisco, California.

Mr. Moch will discuss the company's antiviral pipeline and technology assets, including CMX001, a broad spectrum antiviral in clinical development for the treatment of double-stranded DNA viruses such as cytomegalovirus, adenovirus, BK virus, JC virus, Epstein-Barr virus and herpes simplex virus; and CMX157, being developed as a potential once-weekly nucleoside analogue against HIV infections.

The BIO Investor Forum is a conference for international investors focused on private and emerging public biotechnology companies.  In an effort to support industry-wide success, the conference presents a broad and unbiased view of investment opportunities with the support of physicians, scientists, and industry analysts.  

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  The company's lead candidate, CMX001, is in Phase 1 and Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of life-threatening viruses, such as BK virus, cytomegalovirus and adenovirus.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies as a potent nucleoside analogue against multi-drug resistant HIV infections.  Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.  

Privately-held, Chimerix has received financing from Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.  For additional information on Chimerix, please visit http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
2. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
3. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
8. Delcath to Present at the William Blair Emerging Growth Stock Conference
9. China-Biotics to Present at Jefferies Healthcare Conference
10. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
11. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... , April 28, 2016 TapImmune,Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for the ... be presenting at the 3rd Annual Growth Capital Expo ... th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... on Wednesday, May 4 th by Dr. John ...
(Date:4/27/2016)... --   , Total Sales ... Sales  Clinical sales grow 16% year-over-year  , ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... quarter ended March 31, 2016 and provided an update ... strategy. First Quarter 2016 Revenue Results by ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity ... Tobacco-Free Kids, a leading force in the fight to reduce tobacco use and ... policies that can help reduce tobacco use. The initiative brings together two organizations ...
(Date:4/28/2016)... Illinois (PRWEB) , ... April ... ... the leading provider of enterprise Data Center Infrastructure Management solutions, announces today ... focuses on feature enhancements in the area of capacity management and optimization, ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and ... Surgery Collaborative Residency Network. The platform is scheduled to launch in July 2016 ...
(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation Commission ... Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with Distinction ... an accreditation distinction. ACHC provides a wide range of pharmacy accreditation services that ...
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... The ... and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for ... the medical community effective October 1, 2016. , Sarcopenia is defined as a combination ...
Breaking Medicine News(10 mins):